Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroups

Leukemia

Volumn 25, Issue 11, 2011, Pages 1728-1738

  Luck S C ^a   Russ, A C ^a   Botzenhardt, U ^a   Paschka, P ^a   Schlenk, R F ^a   Dohner H ^a   Fulda, S ^b   Dohner K ^a   Bullinger, L ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

acute myeloid leukemia; apoptosis; BCL2; core binding factor; gene expression profiling; inhibitor of apoptosis proteins

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CORE BINDING FACTOR; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROGNOSIS;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE; CORE BINDING FACTORS; DNA PRIMERS; HUMANS; LEUKEMIA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 80755140040     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.154     Document Type: Article

References (48)

1. Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008; 93: 976-982. (Pubitemid 351957013)
2. Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol 2008; 35: 410-417.
3. Hart SM, Foroni L. Core binding factor genes and human leukemia. Haematologica 2002; 87: 1307-1323. (Pubitemid 36005305)
4. Speck NA. Core binding factor and its role in normal hematopoietic development. Curr Opin Hematol 2001; 8: 192-196. (Pubitemid 32762959)
5. Castilla LH, Perrat P, Martinez NJ, Landrette SF, Keys R, Oikemus S et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci USA 2004; 101: 4924-4929. (Pubitemid 38469179)
6. Appelbaum FR, Kopecky KJ, Tallman MS, SlovakML, Gundacker HM, Kim HT et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006; 135: 165-173. (Pubitemid 44401613)
7. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, Sander S et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 2007; 110: 1291-1300. (Pubitemid 47281428)
8. Marcucci G, Mrozek K, Ruppert AS, Maharry K, Kolitz JE, Moore JO et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005; 23: 5705-5717.
9. Schlenk RF, Benner A, Krauter J, Buchner T, Sauerland C, Ehninger G et al. Individual patient data-based meta-analysis of patients aged to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22: 3741-3750. (Pubitemid 41102131)
10. Luck SC, Russ AC, Du J, Gaidzik V, Schlenk RF, Pollack JR et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Br J Haematol 2010; 148: 925-937.
11. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911. (Pubitemid 46630738)
12. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219. (Pubitemid 38167313)
13. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
14. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
15. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009; 23: 467-476.
16. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131: 669-681. (Pubitemid 350087204)
17. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009; 16: 360-367.
18. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
19. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010; 16: 3329-3334.
20. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene 2009; 28: 2545-2555.
21. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868. (Pubitemid 29003722)
23. Alli E, Yang JM, Ford JM, Hait WN. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 2007; 71: 1233-1240. (Pubitemid 46658676)
24. Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009; 8: 2559-2565.
25. Milella M, Kornblau SM, Estrov Z, Carter BZ, Lapillonne H, Harris D et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851-859. (Pubitemid 32880294)
26. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004; 428: 198-202. (Pubitemid 38374318)
27. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009; 35: 255-261.
28. Bliss C. The toxicity of poisons applied jointly. Ann Appl Biol 1939; 26: 585-615.
29. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385.
30. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456. (Pubitemid 350064365)
31. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol 2010; 77: 483-494.
32. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006; 10: 375-388. (Pubitemid 44693472)
33. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008; 68: 2321-2328. (Pubitemid 351521806)
34. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176-1183.
35. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. Seed analysis of off-target siRNAs reveals an essential role of Mcl-1in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 2007; 26: 3972-3979. (Pubitemid 46884293)
36. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010; 115: 3304-3313.
37. Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H et al. Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines. Mol Cancer Ther 2010; 9: 545-557.
38. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-3176.
39. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009; 113: 299-305.
40. Wilson WH, O'Connor OA, Czuczman MS, Lacasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 doseescalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
41. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096. (Pubitemid 23162130)
42. Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A. High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 2002; 49: 141-144. (Pubitemid 34728789)
43. Jin HS, Lee DH, Kim DH, Chung JH, Lee SJ, Lee TH. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res 2009; 69: 1782-1791.
44. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W et al. IAPs contain an evolutionarily conserved ubiquitinbinding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol 2008; 10: 1309-1317.
45. Wong WW, Gentle IE, Nachbur U, Anderton H, Vaux DL, Silke J. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ 2010; 17: 482-487.
46. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700. (Pubitemid 351818251)
47. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K, Deshayes K et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1/RIP3-dependent reactive oxygen species production. Cell Death Differ 2010; 18: 656-665.
48. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, Korneluk RG. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-6275.